Lars G Hemkens
Overview
Explore the profile of Lars G Hemkens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
2432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmitt A, Herbrand A, Kasenda B, Hemkens L
Am J Epidemiol
. 2025 Mar;
PMID: 40080631
No abstract available.
2.
Disanto G, Schaedelin S, Oechtering J, Lorscheider J, Galbusera R, Finkener S, et al.
Mult Scler J Exp Transl Clin
. 2025 Feb;
11(1):20552173251315457.
PMID: 40017897
Background: Persistence to B cell depleting therapies (BCDT) like ocrelizumab and rituximab may be higher compared with other disease-modifying therapies (DMT) in multiple sclerosis (MS). Clinical trials directly comparing these...
3.
Haas Y, Williams O, Masia J, Pons G, Taylor E, Katapodi M, et al.
Cochrane Database Syst Rev
. 2025 Feb;
2:CD016019.
PMID: 39945379
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of microsurgery versus complex physical decongestive therapy in people with chronic breast...
4.
Meyer M, Strazdins E, Guessoum A, Westenberg J, Appenzeller-Herzog C, Cattaneo M, et al.
Addiction
. 2025 Feb;
PMID: 39924451
Background And Aims: Opioid agonist treatment (OAT) is established for opioid use disorder, but limited data on adverse effects exist. We aimed to review relative risks of adverse effects across...
5.
Nilsonne G, Wieschowski S, DeVito N, Salholz-Hillel M, Ahnstrom L, Bruckner T, et al.
J Clin Epidemiol
. 2025 Feb;
181:111710.
PMID: 39900256
Objectives: To systematically evaluate timely reporting of clinical trial results at medical universities and university hospitals in the Nordic countries. Study Design And Setting: In this cross-sectional study, we included...
6.
7.
Kepp K, Hoilund-Carlsen P, Cristea I, Cumming R, Daly T, Emilsson L, et al.
Curr Med Res Opin
. 2025 Jan;
41(2):347-354.
PMID: 39853750
This paper reviews the scientific evidence on new anti-amyloid monoclonal antibodies for treating Alzheimer's disease as a case study for improving scientific evidence communication. We introduce five guidelines condensed from...
8.
Boesen K, Hemkens L, Janiaud P, Hirt J
medRxiv
. 2024 Nov;
PMID: 39606403
Conducting systematic reviews of clinical trials is arduous and resource consuming. One potential solution is to design databases that are continuously and automatically populated with clinical trial data from harmonised...
9.
Goldkuhle M, Hirsch C, Iannizzi C, Zorger A, Bender R, van Dalen E, et al.
BMC Med Res Methodol
. 2024 Nov;
24(1):291.
PMID: 39587509
Background: Time-to-event analysis is associated with methodological complexities. Previous research identified flaws in the reporting of time-to-event analyses in randomized trial publications. These hardships impose challenges for meta-analyses of time-to-event...
10.
Elgersma I, Elstrom P, Hemkens L, Helleve A, Kacelnik O, Fretheim A
Trials
. 2024 Nov;
25(1):753.
PMID: 39529196
No abstract available.